rss
Br J Ophthalmol 88:1295-1298 doi:10.1136/bjo.2004.043232
  • Clinical science
    • Extended reports

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Table 6

 Reason provided for discontinuation or change of the LTFC* (n = 1676)

Reason No of patients %
*The physician may not have thought a relation between the drug and adverse event existed.
Insufficient efficacy 70 4.2
Adverse event 17 1.0
No information provided 15 0.9
Surgery 6 0.4
Other 5 0.3
Lost to follow up 4 0.2
Patient desire 3 0.2
Patient death 2 0.1
Poor compliance 1 0.06

This Article

  1. Abstract
  2. Full text
  3. PDF

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.